Daniel P. Petrylak, MD, presented “PARPi in mCRPC” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado. This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Petrylak, P. Daniel. “PARPi in mCRPC.” February 2024. Accessed Sep 2024. https://grandroundsinurology.com/parpi-in-mcrpc/
PARPi in mCRPC – Summary
Daniel P. Petrylak, MD, analyzes the role of PARP inhibitors (PARPi) in managing metastatic castration-resistant prostate cancer (mCRPC), reviewing clinical trials that have established their efficacy in mCRPC in patients with certain HRR mutations (such as BRCA1 and BRCA2). Dr. Petrylak emphasizes the importance of identifying patients who are most likely to benefit from PARP inhibitor therapy and advocating for routine profiling in mCRPC management.
Dr. Petrylak outlines current guidelines and treatment algorithms for the use of PARP inhibitors in the treatment of mCRPC. The talk also explores combination therapies involving PARP inhibitors and other agents, highlighting ongoing clinical trials investigating these novel combinations.
In this 10-minute presentation, Dr. Petrylak summarizes the current and future role of PARP inhibitors in mCRPC, providing valuable insights into their clinical application and potential to improve patient outcomes.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
